Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC

FDA Approval of Frontline Nivolumab/Ipilimumab Combo in RCCПодробнее

Dr. McDermott on Nivolumab Plus Ipilimumab in RCCПодробнее

Dr. McKay on FDA Approval of Frontline Cabozantinib in RCCПодробнее

Dr. Eng on the FDA Approval of Nivolumab Plus Ipilimumab in CRCПодробнее

Dr. Motzer on Nivolumab/Ipilimumab Activity in RCCПодробнее

Dr. Pal on the Frontline Approval of Nivolumab and Ipilimumab in mRCCПодробнее

Metastatic RCC: Using Frontline Ipilimumab/NivolumabПодробнее

Rana McKay, MD, discusses Checkmate214 investigating nivolumab + ipilimumab in 1st line RCC patientsПодробнее

Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLCПодробнее

Dr. Petrylak on FDA Approval of Nivolumab in Bladder CancerПодробнее

FDA Approval of Second-Dosing Schedule of NivolumabПодробнее

CheckMate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for RCCПодробнее

Dr. McDermott on Single-Agent Nivolumab in RCCПодробнее

Front-line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced RCCПодробнее

mRCC Patient Selection for Ipilimumab/NivolumabПодробнее

Combination Therapies Emerge in the Frontline for Renal Cell CarcinomaПодробнее

Dr. Chiang on Toxicities with Ipilimumab Plus Nivolumab in Small Cell Lung CancerПодробнее

Selecting Atezolizumab Plus Bevacizumab Versus Ipilimumab Plus Nivolumab in RCCПодробнее

Frontline Treatment Standard in mRCCПодробнее